Mesoblast (MSB) is held by 16 ASX ETFs. Over the last 6 months it fell 7.7%: on $10,000, −$775. We explain 3 big moves in that time.
About MSB
- SectorHealth Care
- IndustryPharmaceuticals, Biotechnology & Life Sciences
- Size$2.6b
- Held by16 ETFs
- Big moves3 in 6M
Each dot is a move we explain. Tap one, or a row of Why it moved, to see what caused it.
Why it moved
- +8.8%15 Jul 2026· Operational
Mesoblast shares surged after the company announced it had enrolled 300 patients in its Phase 3 back pain trial, hitting a key milestone, while continuing momentum from a recent strong Ryoncil commercial launch and FDA BLA progress drove sustained buying interest.
- +7.9%10 Jul 2026· Unknown
Mesoblast shares rose sharply, most likely driven by company-specific news or clinical trial developments not captured in available data sources, as the move is too large to be explained by broad market or sector tailwinds alone.
- −9.4%26 Jun 2026· Operational
The stock dropped after a 5% slide report on Friday, continuing a pullback following a recent non-dilutive funding drawdown announcement.
Held by 16 ETFs
Of every $10,000 in each fund, how much is in MSB today.
- SSOSTATE STREET SPDR S&P/ASX SMALL ORDINARIES ETF$670.67%
- ISOiShares S&P/ASX Small Ordinaries ETF$660.66%
- FAIRBetaShares Australian Sustainability Leaders ETF$460.46%
- VSOVanguard MSCI Australian Small Companies Index ETF$340.34%
- OZXXGlobal X Australia ex Financials & Resources ETF$270.27%
- EX20BetaShares Australian Ex-20 Portfolio Diversifier ETF$190.19%
- GEARBetaShares Geared Australian Equities Complex ETF$160.16%
- VETHVanguard Ethically Conscious Australian Shares ETF$100.10%
- ROYLBetaShares Global Royalties ETF$8.030.08%
- STWSTATE STREET SPDR S&P/ASX 200 ETF$7.900.08%